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Abstract
Background: Autosomal recessive bleeding disorders (ARBDs) include deficiencies of clotting factors I, II, V, VII,
X, XI, XIII, vitamin K dependent clotting factors, combined factor V & VIII, Von Willebrand Disease (vWD) type 3,
Glanzmann’s thrombasthenia (GT) and Bernard–Soulier syndrome. Patients with primary bleeding disorders from
all the major provincial capitals of Pakistan were screened for ARBDs. Prothrombin (PT), activated partial
thromboplastin time (APTT), bleeding time (BT) and fibrinogen levels were measured. Cases with isolated
prolonged APTT were tested for factors VIII and IX using factor assays This was followed by FXI:C level
assessment in cases with normal FVIII and FIX levels. vWD was screened in patients with low FVIII levels. Factors
II, V and X were tested in patients with simultaneous prolongation of PT and APTT. Peripheral blood film
examination and platelet aggregation studies were performed to assess platelet disorders. Urea clot solubility
testing was done to detect Factor XIII levels where platelet function tests were normal. Descriptive analysis was
done using SPSS version 16.
Results: Of the 429 suspected bleeding disorder patients, 148 (35%) were diagnosed with hemophilia A and
211 (49.1%) patients had ARBDs. 70 patients (16.3%) remained undiagnosed. Out of 211 patients with ARBD; 95
(33.8%) had vWD type 3. Fibrinogen deficiency was found in 34 patients (12%), GT in 27 (9.6%), factor XIII
deficiency in 13 (4.6%), factor VII deficiency in 12 (4.3%), factor V deficiency in 9 (3.2%). Eight patients (2.8%) had
vitamin K-dependent clotting factor deficiency, Bernard–Soulier syndrome was diagnosed in seven patients (2.
5%), factor X deficiency in 2 (0.7%), factor II deficiency in 2 (0.7%), factor XI deficiency and combined factor V
and VIII deficiency in 1 (0.4%) patient each.
Conclusion: vWD type 3 was the most common ARBD found in our sample of patients in Pakistan, followed by
fibrinogen deficiency and GT in respective order.
Keywords: Autosomal recessive, Inherited bleeding disorders, Coagulation factors, von Willebrand disease type
3, Glanzmann’s thrombasthenia, Bernard–Soulier syndrome
Background
The incidence of autosomal recessive bleeding disor-
ders (ARBDs) worldwide is uncommon at about 3–5%
[1, 2] as compared with other causes of bleeding. How-
ever, these disorders predominate in those regions of
the world where consanguineous marriages are
encouraged [3]. Pakistan has a high rate of such
marriages [4, 5]. The prevalence of some of these dis-
orders in the local population has only been reported
in a few studies [6–11] and a lack of diagnostic facil-
ities and expertise has prevented a comprehensive
study to identify ARBDs.
The ARBDs include deficiencies of clotting factors
I, II, V, VII, X, XI, XIII, vitamin K-dependent clotting
factors [VKDCF; II, VII, IX and X], combined factors
V and VIII, von Willebrand disease type 3 (vWD),
Glanzmann’s thrombasthenia (GT) and Bernard–Sou-
lier syndrome (BSS). The presentation and bleeding
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pattern in these patients varies according to the
etiology of each disorder [12, 13]. Life threatening
bleeding episodes e.g., central nervous system or
musculoskeletal bleeding, occur rarely.
Fibrinogen deficiency has a prevalence of 1 in a mil-
lion [14, 15]. It is subdivided into two distinct pheno-
types: quantitative defect (afibrinogenemia and
hypofibrinogenemia) and qualitative defect (dysfibrino-
genemia and hypodysfibrinogenemia), Prothrombin de-
ficiency (PD) has a prevalence of approximately 1 in
two million [16] and has two phenotypes: true hypo-
prothrombinemia (type I deficiency) and dysprothrom-
binemia (type II deficiency) [16]. Factor V [FV]
deficiency is manifested by skin and mucus membrane
bleeding, epistaxis and menorrhagia. Prevalence is 1 in
a million [17]. Factor VII deficiency presents as a
hemophilia-like bleeding disorder with an estimated
prevalence of 1 in 300,000–500,000 [18]. The most
severe form of vWD is type 3, characterized by a
bleeding disorder associated with a total or near-total
absence of von Willebrand factor (vWF) with defi-
ciency of plasmatic factor VIII (FVIII) [8]. The type 3
vW disease is the rarest form of vWD, accounting for
less than 5% of all cases of bleeding disorders world-
wide. Annual incidence ranges from 1 in two million
to 1 in 350,000 in Europe and the United States, with
estimates of around 1 per 500,000 in countries where
consanguinity is more frequent [19]. Combined defi-
ciency of factor V and VIII is associated with muta-
tions in the LMAN1 and MCFD2 genes [20, 21]. It is
characterized by concomitantly low levels (usually be-
tween 5 and 20%) of both FV and FVIII and is associ-
ated with a mild to moderate bleeding tendency [22].
There are two variants to vitamin K-dependent clotting
factor deficiency VKDCF; VKDCF1, associated with
point mutations in the gamma-glutamyl carboxylase
gene (GGCX), and VKDCF2, which results from point
mutations in the vitamin K epoxide reductase gene
(VKORC1) [23]. Factor X deficiency has an estimated
prevalence of 1 in one million individuals [24]. Factor
XI deficiency can manifest first as a bleeding disorder
or as an incidental laboratory abnormality. Occurrence
is approximately 1 per one million [25]. Factor XIII de-
ficiency is a rare disorder, causing a severe bleeding
tendency. The incidence is 1 per one million to 1 in
five million people [26, 27]. GT is the most frequently
diagnosed inherited disorder of platelet function
(prevalence, 1 in a million) [28]. Patients lack or have
nonfunctional alpha 2b beta 3 (αIIbβ3) integrin. Type I
individuals have <5% of αIIbβ3, while type II have be-
tween 10 and 20%. In type III, there are normal levels
of αIIbβ3, but they are not functional [29]. The auto-
somal recessive disorder BSS has a prevalence of 1 in
one million [30]. Platelets from patients with BSS lack
the major surface membrane glycoprotein complex,
glycoprotein (GP) Ib-IX-V [31].
The aim of this study was to determine and compare
the 12 year period prevalence of ARBDs in several re-
gions of Pakistan.
Methods
The study was approved by the ethics committee of the
National Institute of Blood Diseases and Bone Marrow
Transplantation (NIBD), Karachi, Pakistan, in accord-
ance with the declaration of Helsinki. It was a descrip-
tive study with cross-sectional time prospect, conducted
from March 2010 till December 2014.
In local set-up, patients are usually diagnosed to have
a bleeding disorder at primary and secondary health
care centers or general clinics. The confirmatory inves-
tigations usually include only the platelets count,
bleeding time (BT), Prothrombin time (PT) and acti-
vated partial thromboplastin time (APTT). Such cases
are hence labelled as merely the bleeding disorder pa-
tients. These centers and clinics were asked to refer all
their patients with bleeding disorders, both classified
and unclassified, to the designated tertiary care cen-
ters. The tertiary health care centers included NIBD
and Fatimid Foundation Karachi [FFK] at the province
of Sindh, Chughtai’s Laboratory and the Children’s
Hospital Lahore [CHL] at Punjab. Pakistan Atomic En-
ergy Commission Hospital [PAEC] at the federal cap-
ital, Islamabad, and Hayatabad Medical Complex
[HMC] and Lady Reading Hospital [LRH]) Peshawar at
the province of Khyber Pakhtunkhwa [KPK] (Fig. 1).
At their visit, patients were enrolled into the current
study after acquiring informed written consents. All
the non-classified bleeding disorder cases were in-
cluded into the study. Those categorized as haemo-
philia A were also included so as to exclude vWD.
Patients taking non-steroidal anti-inflammatory drugs
(NSAIDS), steroids, clotting factors or those who had
had a platelet transfusion 2 weeks prior to the start of
the study were excluded.
A general questionnaire, with basic demographic de-
tails, clinical and family histories, and the Tosetto
bleeding score questionnaire were filled out for each
patient by a doctor at the corresponding recruitment
center [32]. The doctors were trained before the com-
mencement of the study with administration of the
questionnaires.
8.1 ml venous blood was then collected in three so-
dium citrate (0.109 M, 3.2%) containing sample collec-
tion tubes, each one 2.7 ml in volume. BT, PT, APTT,
Factor VIII and IX assays, were determined at the ter-
tiary healthcare centers. In patients with normal plate-
let count and normal clotting times of PT and APTT,
platelet aggregation studies were performed. Peripheral
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blood samples were analyzed to identify any platelet
morphological abnormalities. The platelet aggregation
studies were performed on Helena Aggram platelet
aggregometer (Helena laboratory, Beaumont Texas,
USA) using standard aggregation reagents (ADP,
2.25 μM; adrenaline, 5 μM; collagen, 4 μg/ml; ristoce-
tin, 1.5 mg/ml; arachidonic acid, 500 μg/ml).
An aliquot of the platelet poor plasma, for each
patient, was transported to NIBD, the central labora-
tory, under controlled refrigeration (Fig. 1). Here, the
first-line coagulation profile, including PT and APTT
were repeated on all the samples, using recombinant
tissue factor (Stago, Asnières sur Seine, France). The
international normalization ratio (INR) was calculated
from the PT using the thromboplastin international
sensitivity index (ISI) and the mean normal PT. Fi-
brinogen levels were measured by Clauss method
[33]. Samples with isolated prolonged APTT were fur-
ther tested for FVIII and factor IX (FIX) using the
one stage APTT-based factor assay [34]. If the FVIII
and FIX levels were normal then FXI levels were
measured (FXI:C). In cases with prolonged PT and
APTT, factors II, V and X were tested using an assay
based on PT using patient platelet poor plasma,
glyoxaline buffer, standard or reference plasma,
thromboplastin and calcium. Patients with low levels
of FVIII were tested for vWF antigen and vWF risto-
cetin cofactor. A urea clot solubility test was
performed using commercially available thrombin on
those patients not diagnosed by other coagulation
tests and suspected of having factor XIII deficiency.
To identify the period prevalence for various ARBDs,
record from the current study was merged with that
from all the studies reported in the last 12 years. For this
purpose, the common national (PakMedinet) and inter-
national (Pubmed, Google Scholar, ISI Web of science,
EMBASE and SCOPUS) databases were screened for
studies on ARBDs in Pakistani population.
Results and Discussion
The study cohort consisted of 429 patients, 250 males
and 179 females, with a male to female ratio of 1.3:1.
The median age of patients was 11 ± 5 years. A history
of consanguinity was present in 89% of cases. Of the 429
patients with diagnosed and suspected bleeding disor-
ders, 211 [49.1%] were diagnosed to have an ARBD, 116
of these were males and 95 females. Among 95 females,
58 were adult. A majority of patients (n = 148; 34.49%)
had hemophilia A while 70 patients remained undiag-
nosed. Majority of the ARBD patients had VWD type 3
(Table 2).
The most common symptoms reported by the cohort
of patients included gum bleeding (57%), and easy bruis-
ing (39%). Spontaneous epistaxis and gum bleeding were
found in 6%, whereas menorrhagia was reported in 19%
of the adult female patients.
Anemia was found in 48% of the patients. Life-
threatening intracranial hemorrhage affected 4% of the
patients. Phenotypic presentation of ARBDs is detailed
in Table 1.
Gum bleeding was more prominent in patients with




Fig. 1 Flow diagram of patient recruitment, sample collection and its disposition at different levels of health care facilities/laboratories. a Initial presentation
of patients with bleeding disorders at primary and/or secondary health care centers. b Referral of patients to the tertiary health care centers or laboratories
for definitive diagnosis. Patients were recruited into the study at this point (c). Samples sent over to the central reference laboratory NIBD where the tests
were repeated to establish reliability. CHL, Children Hospital Lahore; CL, Chughtai’s Laboratory; FFK, Fatimid Foundation Karachi; HMC, Hayatabad Medical
Complex; KP, Khyber Pakhtunkhwa; LRH, Lady Reading Hospital; NIBD, National Institute of Blood Diseases; PAEC, Pakistan Atomic Energy Commission.
N = number of patients with ARBD, () indicate total number of patients recruited from each center initially
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syndrome; hemarthrosis was most common in patients
suffering from factor VII deficiency, hematoma was
more noticeable in patients with factor XIII, factor V
and vitamin K dependent clotting factor deficiency.
Patients with factor XIII deficiency had the highest inci-
dence of prolonged umbilical cord bleeding. Prolonged
bleeding after trauma was associated with factor VII and
vitamin K dependent clotting factor deficiency, GT and
BSS. Easy bruising is a prominent feature of GT, BSS
and factor XI deficiency according to our study cohort
(Table 1).
In the current study, 32 patients were found to have
severe fibrinogen deficiency while two patients had
moderate severity of the disease. In FXIII deficiency,
all the cases had severe disease. Among FVII deficient
patients, 2 had mild, 8 had moderate and 2 patients
had severe disease. Of the nine patients with FV defi-
ciency, 7 had moderate and 2 had severe disease. All
the cases with FX deficiency had severe disease. Two
patients had FII deficiency, both bearing moderate
severity of the disease. One patient with severe FXI
deficiency was also identified. Mild Combined FV &
FVIII deficiency was also found in a single case, as per
laboratory phenotype classification [13].
Findings from the current study were compared with
those conducted in Italy [35], Iran [35] and India [36],
countries with high rates of autosomal recessive dis-
eases due to consanguineous marriages (Fig. 2). In our
study patients, vWD type 3 was the most common dis-
order, with 95 patients (33.8%), although in a similar,
Fig. 2 Comparative studies of different nationalities with ARBDs [7, 29, 36]
Table 1 Frequency and severity of bleeding






Bruises ICH BGa BSb
VWD-3 (95) 51 8 15 31 11/19 10 - 12 - II 13.5
Fib. Def. (34) 2 6 17 9 - - 23 15 - II 12.5
GT (27) 23 - 4 19 8/9 16 27 19 - II 11
FXIII Def. (13) 11 - 6 9 6/6 11 5 9 1 II 11.5
FVII Def. (12) 9 8 7 11 6/9 - 11 9 2 III 12
FV Def. (9) 7 2 6 5 5/7 - 4 5 1 II 11
Vit K Def. (8) 7 - 5 2 3/3 5 7 5 - II 12
BSS (7) 7 - 7 7 - - 7 7 - II 11
FX Def. (2) 1 2 2 - 2/3 2 - - II 12
FII Def. (2) 2 1 2 1 1/2 - - 1 - II 10
FXI Def. (1) 1 - 1 1 - - 1 1 - II 10
FV & FVIII Def. (1) 1 1 1 - - - - 1 - II 11.5
ARBD autosomal recessive bleeding disorders, BG bleeding grade, BS bleeding score, BSS Bernard Soulier syndrome, Def. deficiency, Fib. fibrinogen, FII Factor II, FV
Factor V, FVII Factor VII, FX Factor X, FVIII Factor VIII, FXI Factor XI, FXIII Factor XIII, GT Glanzmann Thrombasthenia, ICH intracranial hemorrhage, N number of
patients, No. number, Vit vitamin, VWD-3 von Willebrand Disease type 3, x affected females, y females at risk
aCalculated on the basis of WHO bleeding grades
bbased on Tossetto et al bleeding score calculation scale
cReported in adult female patients only
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local study, the percentage was 51.4% [7], in Iran it was
50% [35], and in Italy, just 4% [35]. It is hence
concluded that in south Asian population vWD type 3
has a high frequency among ARBDs. The second most
common deficiency found in this study was fibrinogen
deficiency (n = 34, 12%). The disease was found to have
a frequency of 11% in the Iranian study [35], 8% in the
Italian study [35] and 10% in the Indian study [36].
Our study findings are comparable to those from the
mentioned contemporary studies. GT, a relatively well
understood platelet disorder, was diagnosed in 27
(9.6%) of patients. Its frequency was 6.9% in the Iranian
study, 4.7% in the Italian study, and 8.1% in an earlier
Pakistani study (Fig. 2).
South Asian countries, particularly Pakistan, have a
high frequency of consanguineous partnerships [4],
which explains the increased prevalence of ARBD in
this region. The local 12 years period prevalence of
ARBDs [37, 38] compared with the international
prevalence is shown in Table 2. Data was not avail-
able from the Baluchistan, Gilgit-Baltistan and Azad
Kashmir regions. A larger national study is needed to
cover the underprivileged, difficult to access areas of
Pakistan, not included in the current study due to the
poorly structured healthcare system and difficulties
with law and order in these regions. Worldwide data
has clearly shown that there is variation in the preva-
lence of individual ARBDs. Genetic studies to identify
the underlying mutations would help in understand-
ing the phenotype/genotype relationship.
There is also a need to educate the general population
regarding the risks of ARBDs and to initiate genetic
counseling services to help prevent consanguineous
marriage in families with a history of these disorders. Pa-
tients with ARBDs require lifelong management and
education on lifestyle modifications relevant to the
bleeding disorder that they live with.
Conclusion
These data have shown that vWD type 3 has the highest
incidence amongst the ARBDs in this study cohort,
followed by fibrinogen deficiency. GT was found to be
the third most common disorder. The incidence of
ARBDs in this region is higher than previously thought.
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capital








VWD type 3 disorder 05 62 21 7 95 (33.8%) 61 156 1.0 0.5
Fibrinogen deficiency 11 20 3 0 34 (12%) 9 43 0.3 0.5
Glanzmann Thrombasthenia 18 9 0 0 27 (9.6%) 50 77 0.5 1
Factor XIII deficiency 7 2 4 0 13 (4.6%) 29 42 0.3 0.5
Factor VII deficiency 4 6 1 1 12 (4.3%) 84 96 0.6 2
Factor V deficiency 0 9 0 0 9 (3.2%) 28 37 0.2 1
Vitamin K dependent clotting
factors deficiency
0 7 0 1 8 (2.8%) 0 8 0.04 1
Bernard Soulier syndrome 3 0 4 0 7 (2.5%) 5 12 0.07 1
Factor X deficiency 1 1 0 0 2 (0.7%) 41 43 0.3 1
Factor II deficiency 0 2 0 0 2 (0.7%) 10 12 0.07 0.5
Factor XI deficiency 1 0 0 0 1 (0.4%) 1 2 0.01 1~
Combined Factor V & VIII
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1 0 0 0 1 (0.4%) 0 1 0.006 1
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*International prevalence data from world hemophilia database and orphanet journal of rare diseases
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~Period Prevalence calculations were based on CDC formulation
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